Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT

Aug 13 2018

• By Jessica Merrill

Bumpy road crossing plains at sunset

Related Content

Persistence Pays Off For Amicus: Positive Migalastat Data In Hand

Aug 20 2014

GlaxoSmithKline hands rare disease drug back to partner Amicus

Nov 21 2013

FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch

Jul 11 2017

Going Deeper Into Rare Disease, GSK Takes Reins of Amicus Fabry Program

Oct 29 2010

Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback

Nov 30 2016

Related Companies

Amicus Therapeutics, Inc.

Sanofi

GSK plc

Additional Topics

Rare Diseases Launches Approvals Pricing Strategies Commercial BioPharmaceutical

More from Rare Diseases

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.